Filed 10 years ago in a federal court in Texas, the lawsuit was based on one person's claim that the dialysis service provider overused Epogen, an anemia drug.
In a news release about the settlement, The Denver-based company said it and its physicians did nothing wrong and "stand by" their anemia management practices.
DaVita added that a government investigation into the Epogen-overuse claims hasn't yielded government intervention or claims.The company also said the settlement contains no admissions of liability by the company or its affiliated physicians. "Nonetheless, agreements such as this one are sometimes in the best interest of shareholders," DaVita said in a news release. DaVita shares closed Tuesday up 9 cents at $97.71. U.S. stock markets were closed Wednesday in observance of the July Fourth holiday.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV